Compugen to Present at the Jefferies Immuno-Oncology Summit in Boston

Mar 28, 2016, 07:00 ET from Compugen Ltd.

HOLON, Israel, March 28, 2016 /PRNewswire/ --

Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Anat Cohen-Dayag, Ph.D., President and Chief Executive Officer of Compugen, will present an overview of the Company's immuno-oncology programs and underlying predictive discovery capabilities at the Jefferies 2016 Immuno-Oncology Summit in Boston, on Thursday, April 7, 2016.

About Compugen  

Compugen is a leading therapeutic discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The primary focus of the Company's current pipeline is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen's business model is based on selectively entering into collaborations for its novel target candidates and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company's novel target candidates. For additional information, please visit Compugen's corporate website at http://www.cgen.com.


Company contact:
Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: tsipih@cgen.com
Tel: +972-52-598-9892

SOURCE Compugen Ltd.